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OpioidGranulocyte-colony stimulating factor (G-CSF) is a current pharmacological approach to increase peripheral
neutrophil counts after anti-tumor therapies. Pain is most relevant side effect of G-CSF in healthy volunteers
and cancer patients. Therefore, the mechanisms of G-CSF-induced hyperalgesia were investigated focusing on
the role of spinal mitogen-activated protein (MAP) kinases ERK (extracellular signal-regulated kinase), JNK
(Jun N-terminal Kinase) and p38, and PI3K (phosphatidylinositol 3-kinase). G-CSF induced dose (30–300 ng/
paw)-dependent mechanical hyperalgesia, which was inhibited by local post-treatment with morphine. This
effect of morphine was reversed by naloxone (opioid receptor antagonist). Furthermore, G-CSF-induced
hyperalgesia was inhibited in a dose-dependent manner by intrathecal pre-treatment with ERK (PD98059),
JNK (SB600125), p38 (SB202190) or PI3K (wortmanin) inhibitors. The co-treatment withMAP kinase and PI3K
inhibitors, at doses that were ineffective as single treatment, signiﬁcantly inhibited G-CSF-induced
hyperalgesia. Concluding, in addition to systemic opioids, peripheral opioids as well as spinal treatment
with MAP kinases and PI3K inhibitors also reduce G-CSF-induced pain.nto de Patologia, Universidade
445, CEP 86051-990, Cx Postal
fax: +55 43 3371 4387.
.com.br (W.A. Verri).
y.
vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The colony-stimulating factors (CSFs) are a group of cytokines that
support the survival, proliferation, differentiation, and end cell
function of myeloid cells (Metcalf, 1993). For instance, granulocyte-
CSF (G-CSF) enhances the production of neutrophils by inducing the
proliferation and differentiation of its myeloid progenitor (Welte et
al., 1985; Demetri and Grifﬁn, 1991). G-CSF also activates terminally
differentiated neutrophils by enhancing antibody-dependent killing,
phagocytic activity and priming the respiratory burst (Bober et al.,
1995). In agreement, G-CSF and G-CSF receptor deﬁcient mice are
severely neutropenic and susceptible to infections (Lieschke et al.,
1994; Liu et al., 1996; Zhan et al., 1998; Battiwalla and McCarthy,
2009). Therefore, G-CSF plays an essential role in steady-stateneutrophil production and in acute/rapid granulopoiesis during
infections (Zhan et al., 1998).
The most important applicability of G-CSF in human therapy is
related to granulopoiesis. The G-CSF treatment increases neutrophil
counts in patients receiving myelosuppressive chemotherapy, patients
with acute myeloid leukemia receiving induction or consolidation
chemotherapy, patients receiving bone marrow transplant, patients
undergoing peripheral blood progenitor cell collection and therapy, and
patients with severe chronic neutropenia (Granulokine®, Filgrastim
package insert; Dale et al., 1993; Battiwalla and McCarthy, 2009).
Nevertheless, the G-CSF treatment induces some side effects. For
instance, according to a retrospective analysis of 341 healthy donors,
the main adverse events of G-CSF therapy (Granulokine®, Filgrastim
package insert) are pain (84%), headache (54%), fatigue (31%) and
nausea (13%) (Battiwalla and McCarthy, 2009). In fact, G-CSF
treatment induces bone, musculoskeletal and visceral pain in healthy
volunteers and cancer patients (Granulokine®, Filgrastim package
insert; Battiwalla and McCarthy, 2009). Thus, pain is the main side
effect of G-CSF therapy.
The main therapy used to control G-CSF-induced pain is the
treatment with opioids such as morphine (Granulokine®, Filgrastim
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dependence because of opioid receptors desensitization leading to
increasing doses of morphine. Moreover, the side effects of
morphine include nausea, constipation, somnolence/sedation, and
respiratory failure (Devulder et al., 2009). Evidence suggests spinal
inhibition of pain processing as a successful strategy to reduce pain
with reduced incidence of systemic side effect. The spinal inhibition
of mytogen-activated protein (MAP) kinases p38, JNK (Jun N-
terminal Kinase) and ERK (extracellular signal-regulated kinases),
and PI3K (phosphatidilinositil 3-kinase) attenuate carrageenin-
induced peripheral hyperalgesia (Svensson et al., 2003; Choi et al.,
2010; Fitzsimmons et al., 2010), formalin-induced overt-pain (Pezet
et al., 2008) and nerve lesion-induced neuropathic pain (Obata et al.,
2004; Xu et al., 2007; Gao and Ji, 2010). Thus, consistent data
support that spinal inhibition of MAP kinases and PI3K reduce
inﬂammatory and neuropathic pain.
In this sense, G-CSF also induces MAP kinases and PI3K activation
dependent effects. G-CSF induces survival and/or proliferation via
MAP kinases (p38, JNK and ERK) and/or PI3K activation dependent
pathways (Rausch and Marshall, 1997, 1999; Dong and Larner, 2000;
Hunter and Avalos, 2000; Kendrick et al., 2004). Furthermore, anti-
G-CSF antibody inhibits cancer-induced pain and spinal activation of
ERK (Schweizerhof et al., 2009). However, it is not known whether
peripheral administration of G-CSF induces pain via spinal activation
of p38, ERK and JNK, and/or PI3K. Therefore, we evaluated the spinal
mechanisms involved in G-CSF injection-induced hyperalgesia in
mice focusing on the participation of MAP kinases and PI3K.
2. Materials and methods
2.1. Animals
The experiments were performed on male Swiss mice (20–25 g,
Universidade Estadual de Londrina, Londrina, PR, Brazil) housed in
standard clear plastic cages (ﬁve per cage) with free access to food
andwater. All behavioral testingwas performed between 9:00 am and
5:00 pm in a temperature-controlled room. Animals' care and
handling procedures were in accordance with the International
Association for Study of Pain (IASP) guidelines and with the approval
of the Ethics Committee of the Universidade Estadual de Londrina. All
efforts were made to minimize the number of animals used and their
suffering. It is noteworthy that different experimenters prepared the
solutions, made the administrations and performed the evaluation of
overt pain-like behavior, mechanical and thermal hyperalgesia.
2.2. Electronic pressure–meter test for mice
Mechanical hyperalgesia was tested in mice as previously reported
(Cunha et al., 2004). Brieﬂy, in a quiet room, mice were placed in
acrylic cages (12×10×17 cm)withwire grid ﬂoors, 15–30 min before
the start of testing. The test consisted of evoking a hind paw ﬂexion
reﬂex with a hand-held force transducer (electronic von Frey
anesthesiometer; Insight, Ribeirão Preto, SP, Brazil) adapted with a
0.5 mm2 contact area polypropylene tip. The investigator was trained
to apply the tip perpendicularly to the central area of the hind paw
with a gradual increase in pressure. The end point was characterized
by the removal of the paw followed by clear ﬂinching movements.
After the paw withdrawal, the intensity of the pressure was recorded
automatically. The value for the response was an average of three
measurements. The animals were tested before and after treatment.
The results are expressed by delta (Δ) withdrawal threshold (in g)
calculated by subtracting the zero-timemeanmeasurements from the
mean measurements (indicated time points) after stimulus. The basal
mechanical withdrawal threshold was 8.8±0.1 g (mean±SEM of 63
groups, 5 mice per group) before injection of stimulus or vehicle.There was no difference of basal mechanical withdrawal thresholds
between groups in the same experiment.2.3. Overt pain-like behavior evaluation
Mice were placed in clear glass compartments and the number of
paw ﬂinches and time spent licking the paw were determined during
30 min after i.pl. injection of saline (25 μl), G-CSF (100 ng/paw) or
formalin 1.5% (25 μl). Total counts were presented at 5 min intervals
(Valerio et al., 2009).2.4. Hot plate test
Mice were placed in a 10 cm-wide glass cylinder on a hot plate
(Insight, Ribeirão Preto, SP, Brazil) maintained at 55 °C. Two control
latencies at least 10 min apart were determined for each mouse. The
normal latency (reaction time) was 5–9 s. The latency was also
evaluated 30 and 60 min after test compound administration. The
reaction time was scored when the animal jumped or licked its paws.
A maximum latency (cut-off) was set at 30 s to avoid tissue damage
(Valerio et al., 2007).2.5. Intrathecal (i.t.) drug administration
The i.t. injections were performed under light halothane anesthe-
sia (1–2%). The dorsal fur of each mouse was shaved, the spinal
column was arched, and a 29-gauge needle was directly inserted into
the subarachnoid space, between the L4 and L5 vertebrae (Mestre et
al., 1994). Correct i.t. positioning of the needle tip was conﬁrmed by
manifestation of a characteristic tail ﬂick response. A 5 μl volume
containing the test agent was slowly injected. Note that drugs
delivered to the subarachnoidal space by i.t. injection can diffuse
into the CSF, which bathes the spinal cord, the dorsal roots, and part of
dorsal root ganglion (Funez et al., 2008).2.6. Drugs
Drugs were obtained from the following sources: formalin (1.5%,
25 μl i.pl.) from Merk (Darmstadt, Germany), G-CSF (Granulokine,
ﬁlgrastin, recombinant human G-CSF, 30–300 ng/paw) from Hoff-
mann La-Roche (Basileia, Swiss), morphine sulphate (2–12 μg/paw)
from Cristalia (São Paulo, Brazil), naloxone hydrochloride (1 mg/Kg),
PD98059 (1–10 μg/intrathecal [i.t.]), SB202190 (1–10 μg/i.t.),
SP600125 (1–10 μg/i.t.), and wortmanin (0.3–3 μg/i.t.) were obtained
from Sigma-Aldrich (St Louis, MO, USA). G-CSF, morphine, naloxone
and formalin were dissolved in saline, and all other compounds were
dissolved in 20% DMSO in saline.2.7. Statistical analysis
Results are presented as means±s.e.m. of measurements made on
5 animals in each group. Two-way analysis of variance (ANOVA) was
used to compare the groups and doses at all times (curves) when the
hyperalgesic responses were measured at different times after the
stimulus injection. The analyzed factors were treatments, time and
time versus treatment interaction. When there was a signiﬁcant time
versus treatment interaction, one-way ANOVA followed by Tukey's
t-test was performed for each time. On the other hand, when the
hyperalgesic responses were measured once after the stimulus
injection, the differences between responses were evaluated by one-
way ANOVA followed by Tukey's t-test. Additionally, comparative
statistical analysis between two groups were done using t test.
Statistical differences were considered to be signiﬁcant at Pb0.05.
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3.1. Intraplantar (i.pl. — subcutaneous injection in the paw) injection of
G-CSF induces mechanical hyperalgesia
Saline (25 μl) or G-CSF (30–300 ng/paw) was injected via i.pl.
route, and mechanical hyperalgesia was evaluated after 1–48 h with
electronic pressure–meter test (Fig. 1). All doses of G-CSF tested
induced signiﬁcant mechanical hyperalgesia 1–7 h after administra-
tion, but only 100 and 300 ng of G-CSF induced signiﬁcant
hyperalgesia until 24 h, which decreased to control levels thereafter
(48 h). One hundred and 300 ng of G-CSF induced signiﬁcant
hyperalgesia compared to the dose of 30 ng of G-CSF 7 and 24 h
after stimulus, and 300 ng of G-CSF also induced signiﬁcant
hyperalgesia compared to 30 ng of G-CSF 5 h after stimulus. There
was no statistical difference between 100 and 300 ng of G-CSF.
Therefore, the G-CSF dose of 100 ng was chosen for the next
experiments.
3.2. Morphine treatment inhibits G-CSF-induced hyperalgesia
Mice were treated with morphine (2, 6, and 12 μg/paw) or saline
(20 μl) 4 h after i.pl. injection of G-CSF (Fig. 2A). Morphine dose-
dependently inhibited G-CSF-induced hyperalgesia at 5 h after
stimulus injection (Fig. 2A). There was a tendency of reduction of
G-CSF-induced hyperalgesia by 2 μg/paw of morphine, although not
signiﬁcant. On the other hand, the doses of 6 and 12 μg/paw of
morphine signiﬁcantly inhibited G-CSF-induced hyperalgesia, and
their effect was also signiﬁcantly different of the dose of 2 μg of
morphine. Corroborating the speciﬁcity of morphine inhibition, the
treatment with naloxone (1 mg/kg, i.p., 1 h before morphine)
signiﬁcantly prevented morphine (6 μg/paw) inhibition of G-CSF-
induced hyperalgesia at 5 h (Fig. 2B). The efﬁcacy of 6 μg of morphine
was local since had no effect on G-CSF-induced hyperalgesia when
administrated in the contra-lateral paw (Fig. 2C). The effect of
morphine was evaluated at one time point because at the local doses
tested, its effect lasts for approximately 1 h (Verri et al., 2006, 2008a).
3.3. G-CSF administration does not induce overt pain-like behavior or
thermal hyperalgesia
Mice received i.pl. injection of saline (25 μl), G-CSF or formalin
1.5% (25 μl), and the number of paw ﬂinching (Fig. 3A) and time spentFig. 1. Intraplantar injection of G-CSF induces mechanical hyperalgesia. Saline (25 μl) or
G-CSF (30–300 ng/paw) was injected via intraplantar (i.pl.) route in mice and
mechanical hyperalgesia was evaluated after 1–48 h with electronic pressure–meter
test. Results are presented as means±s.e.m. of 5mice per group, and are representative
of 2 separated experiments. * Pb0.05 compared to the saline group, and # Pb0.05
compared to the 30 ng/paw dose of G-CSF. (Two-way ANOVA, and one-way ANOVA
followed by Tukey's t-test). The baseline mean values were: saline (8.3±0.5), G-CSF
30 ng (8.5±0.5), G-CSF 100 ng (8.8±0.2), and G-CSF 300 ng (8.6±0.4).
Fig. 2.Morphine treatment inhibits G-CSF-induced hyperalgesia. Panel A: Mice received
i.pl. injection of G-CSF (100 ng) or vehicle (20 μl of saline), and after 4 h were treated
with morphine (2, 6, and 12 μg/paw) or vehicle (20 μl of saline). Panel B: Mice received
i.pl. injection of G-CSF (100 ng), and after 3 h were treated with naloxone (1 mg/kg, i.p.
route) or vehicle (200 μl of saline). After additional 1 h, mice received morphine (6 μg/
paw) treatment. Mechanical hyperalgesia was evaluated 5 h after G-CSF administration
with electronic pressure meter. Results are presented as means±s.e.m. of 5 mice per
group, and are representative of 2 separated experiments. * Pb0.05 compared to the
saline group, # Pb0.05 compared to G-CSF control group (Panel B only), and ** Pb0.05
compared to G-CSF control group and the lower dose of morphine (2 μg/paw) (One-
way ANOVA followed by Tukey's t-test). The baseline mean values were: Panel A —
saline (9.3±0.5), G-CSF (8.6±0.4), G-CSF+morphine 2 (8.5±0.3), G-CSF+morphine
6 (9.2±0.6), and G-CSF+morphine 12 (9.7±0.5); Panel B — saline (9.3±0.5), G-CSF
(8.6±0.4), G-CSF+morphine (9.1±0.6), and G-CSF+morphine+naloxone
(8.3±0.5); Panel C — saline (8.2±0.2), G-CSF (8.0±0.5), G-CSF+morphine contra-
lateral paw (8.1±0.4).licking (Fig. 3B) were evaluated during 30 min at 5 min intervals. G-
CSF did not induce signiﬁcant paw ﬂinching or licking compared to
saline group (Fig. 3A and B). Additionally, other spontaneous
nociceptive behaviors such as paw lifting or guarding were not
observed (data not shown). On the other hand, the positive control
Fig. 3. G-CSF administration does not induce overt pain-like behavior or thermal
hyperalgesia. Panels A–B: Total number of ﬂinch (Panel A) and time spent licking (Panel
B) were evaluated during 30 min after i.pl. injection of saline (25 μl), G-CSF (100 ng) or
formalin 1.5% (25 μl) in mice. Panel C: The thermal nociceptive threshold was evaluated
before and 5 h after i.pl. injection of saline (25 μl) or G-CSF (100 ng) with the hot plate
test in mice. Bars represent means±s.e.m. of 5 mice per group, and are representative
of 2 separated experiments. No statistical differences were detected in panels A–B (one-
way ANOVA followed by Tukey's t-test) and panel C (t-test).
Fig. 4. Role of spinal ERK in G-CSF-induced hyperalgesia. Mice were treated with
PD98059 (1–10 μg) or vehicle (2% DMSO in saline) via intrathecal (i.t.) route 30 min
before i.pl. injection with G-CSF (100 ng/paw). Mechanical hyperalgesia was evaluated
in the ipsilateral (Panel A) and contra-lateral (Panel B) paws to G-CSF injection after 1–
7 h with electronic pressure meter test. Results are presented as means±s.e.m. of 5
mice per group, and are representative of 2 separated experiments. * Pb0.05 compared
to vehicle i.t.+saline group, # Pb0.05 compared to vehicle i.t.+G-CSF group, and
** Pb0.05 compared to the lower dose of inhibitor tested (Two-wayANOVA, and one-way
ANOVA followed by Tukey's t-test). The baseline mean values were: Panel A— vehicle
i.t.+saline (8.8±0.2), vehicle i.t.+G-CSF (8.9±0.3), PD98059 1 μg i.t.+G-CSF
(8.4±0.2), PD98059 3 μg i.t.+G-CSF (8.8±0.2), and PD98059 10 μg i.t.+G-CSF
(8.7±0.6); Panel B — vehicle i.t.+saline (8.6±0.6), vehicle i.t.+G-CSF (8.4±0.2),
PD98059 1 μg i.t.+G-CSF (8.6±0.4), PD98059 3 μg i.t.+G-CSF (8.5±0.2), and
PD98059 10 μg i.t.+G-CSF (8.7±0.2).
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paw ﬂinching and licking compared to saline and G-CSF between 0–5,
15–20, 20–25 and 25–30 min (Fig. 3A and B). The formalin-induced
overt pain-like behavior was consistent with the model since
presented two phases (Valerio et al., 2009). In another set of
experiments, the thermal nociceptive threshold was evaluated before
and 5 h after i.pl. injection of saline (25 μl) or G-CSF with the hot plate
test in mice (Fig. 3C). G-CSF did not alter the thermal threshold of
mice in the hot plate test.3.4. Role of spinal ERK activation in G-CSF-induced hyperalgesia
Mice were treated intrathecally (i.t.) with the MEK1/2 inhibitor
(prevents ERK1/2 activation) PD98059 (1–10 μg) or vehicle (5 μl of
20% DMSO in saline) 30 min before i.pl. G-CSF stimulus, and
mechanical hyperalgesia was evaluated in the ipsilateral (Fig. 4A)
and contra-lateral (Fig. 4B) paws to G-CSF stimulus. These dose ranges
and vehicle concentration were chosen based on previous studies
(Zhuang et al., 2004, 2005). The dose of 1 μg of PD98059 did not alter
G-CSF-induced hyperalgesia (Fig. 4A). On the other hand, the dose of
3 μg of PD98059 inhibited G-CSF-induced hyperalgesia 5 h after
stimulus (Fig. 4A). The dose of 10 μg of PD98059 signiﬁcantly
inhibited G-CSF hyperalgesia 1–7 h compared to vehicle i.t.+G-CSF,
and 3–7 h compared to PD98059 1 μg i.t.+G-CSF groups (Fig. 4A). The
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the contra-lateral paw (Fig. 4B).
3.5. Role of spinal JNK in G-CSF-induced hyperalgesia
Mice were treated i.t. with the JNK inhibitor SP600125 (1–10 μg)
or vehicle (5 μl of 20% DMSO in saline) 30 min before i.pl. G-CSF
stimulus, andmechanical hyperalgesia was evaluated in the ipsilateral
(Fig. 5A) and contra-lateral (Fig. 5B) paws to G-CSF stimulus. These
dose ranges and vehicle concentration were chosen based on previous
studies (Doya et al., 2005). The dose of 1 μg of SP600125 did not alter
G-CSF-induced hyperalgesia (Fig. 5A). On the other hand, the dose of
3 μg of SP600125 inhibited G-CSF-induced hyperalgesia 3 and 5 h
after stimulus injection (Fig. 5A). The dose of 10 μg of SP600125
signiﬁcantly inhibited G-CSF hyperalgesia compared to vehicle i.t.+
G-CSF and SP600125 1 μg i.t.+G-CSF groups 3–7 h after stimulus
injection (Fig. 5A). The SP600125 i.t. treatment did not alter the
mechanical hyperalgesia in the contra-lateral paw (Fig. 5B).Fig. 5. Role of spinal JNK in G-CSF-induced hyperalgesia. Mice were treated with
SP600125 (1–10 μg) or vehicle (2% DMSO in saline) via intrathecal (i.t.) route 30 min
before i.pl. injection with G-CSF (100 ng/paw). Mechanical hyperalgesia was evaluated
in the ipsilateral (Panel A) and contra-lateral (Panel B) paws to G-CSF injection after 1–
7 h with electronic pressure meter test. Results are presented as means±s.e.m. of 5
mice per group, and are representative of 2 separated experiments. * Pb0.05 compared
to vehicle i.t.+saline group, # Pb0.05 compared to vehicle i.t.+G-CSF group, and
** Pb0.05 compared to the lower dose of inhibitor tested (Two-way ANOVA, and one-way
ANOVA followed by Tukey's t-test). The baseline mean values were: Panel A— vehicle
i.t.+saline (10.5±0.2), vehicle i.t.+G-CSF (10.3±0.2), SP600125 1 μg i.t.+G-CSF
(10.3±0.4), SP600125 3 μg i.t.+G-CSF (10.5±0.6), and SP600125 10 μg i.t.+G-CSF
(10.4±0.2); Panel B — vehicle i.t.+saline (10.5±0.2), vehicle i.t.+G-CSF (10.3±0.1),
SP600125 1 μg i.t.+G-CSF (9.7±0.7), SP600125 3 μg i.t.+G-CSF (10.1±0.3), and
SP600125 10 μg i.t.+G-CSF (10.2±0.2).3.6. Role of spinal p38 in G-CSF-induced hyperalgesia
Mice were treated i.t. with the p38 inhibitor SB202190 (1–10 μg)
or vehicle (5 μl of 20% DMSO in saline) 30 min before i.pl. G-CSF
stimulus, andmechanical hyperalgesia was evaluated in the ipsilateral
(Fig. 6A) and contra-lateral (Fig. 6B) paws to G-CSF stimulus. These
dose ranges and vehicle concentration were chosen based on previous
studies (Chen et al., 2009). The dose of 1 μg of SB202190 did alter
G-CSF-induced hyperalgesia (Fig. 6A). The dose of 3 μg of SB202190
inhibited G-CSF-induced hyperalgesia 5 h after stimulus (Fig. 6A). The
dose of 10 μg of SB202190 signiﬁcantly inhibited G-CSF hyperalgesia
3–7 h compared to vehicle i.t.+G-CSG group, and 3–5 h compared to
the dose of 1 μg of SB202190 (Fig. 6A). The SB202190 i.t. treatment
did not alter the mechanical hyperalgesia in the contra-lateral paw
(Fig. 5B).
3.7. Role of spinal PI3K in G-CSF-induced hyperalgesia
Micewere treated i.t. with the PI3K inhibitor wortmanin (0.3–3 μg)
or vehicle (5 μl of 20% DMSO in saline) 30 min before i.pl. G-CSFFig. 6. Role of spinal p38 in G-CSF-induced hyperalgesia. Mice were treated with
SB202190 (1–10 μg) or vehicle (2% DMSO in saline) via intrathecal route 30 min before
i.pl. injection with G-CSF (100 ng/paw). Mechanical hyperalgesia was evaluated in the
ipsilateral (Panel A) and contra-lateral (Panel B) paws to G-CSF injection after 1–7 h
with electronic pressure meter test. Results are presented as means±s.e.m. of 5 mice
per group, and are representative of 2 separated experiments. * Pb0.05 compared to
vehicle i.t.+saline group, # Pb0.05 compared to vehicle i.t.+G-CSF group, and
** Pb0.05 compared to the lower dose of inhibitor tested (Two-wayANOVA, and one-way
ANOVA followed by Tukey's t-test). The baseline mean values were: Panel A— vehicle
i.t.+saline (7.9±0.3), vehicle i.t.+G-CSF (8.5±0.2), SB202190 1 μg i.t.+G-CSF
(8.4±0.2), SB202190 3 μg i.t.+G-CSF (8.8±0.2), and SB202190 10 μg i.t.+G-CSF
(8.6±0.5); Panel B — vehicle i.t.+saline (7.8±0.2), vehicle i.t.+G-CSF (8.4±0.3),
SB202190 1 μg i.t.+G-CSF (8.6±0.2), SB202190 3 μg i.t.+G-CSF (8.7±0.2), and
SB202190 10 μg i.t.+G-CSF (8.5±0.4).
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(Fig. 7A) and contra-lateral (Fig. 7B) paws to G-CSF stimulus. These
dose ranges and vehicle concentration were chosen based on previous
studies (Zhuang et al., 2004; Xu et al., 2007). The dose of 0.3 μg of
wortmanin did not alter G-CSF-induced hyperalgesia (Fig. 7A). On the
other hand, 1 and 3 μg of wortmanin signiﬁcantly inhibited the
hyperalgesia compared to vehicle i.t.+G-CSF and 0.3 μg i.t.+G-CSF
groups 3–7 h after stimulus (Fig. 7A). The dose of 3 μg of wortmanin
inhibitory effect was also signiﬁcant 1 h after stimulus compared to
vehicle i.t.+G-CSF group (Fig. 7A). The wortmanin i.t. treatment did
not alter the mechanical hyperalgesia in the contra-lateral paw
(Fig. 7B). Five h after G-CSF stimulus therewere signiﬁcant differences
between the doses of MAP kinases and PI3K inhibitors (Figs. 4A, 5A, 6A
and 7A), which is also the peak of G-CSF-induced mechanical
hyperalgesia (Fig. 1). Therefore, this time point was used for the
next experiment.Fig. 7. Role of spinal PI3K in G-CSF-induced hyperalgesia. Mice were treated with
wortmanin (0.3–3 μg) or vehicle (2% DMSO in saline) via intrathecal route 30 min
before i.pl. injection with G-CSF (100 ng/paw). Mechanical hyperalgesia was evaluated
in the ipsilateral (Panel A) and contra-lateral (Panel B) paws to G-CSF injection after 1–
7 h with electronic pressure meter test. Results are presented as means±s.e.m. of 5
mice per group, and are representative of 2 separated experiments. * Pb0.05 compared
to vehicle i.t.+saline group, # Pb0.05 compared to vehicle i.t.+G-CSF group, and
** Pb0.05 compared to the lower dose of inhibitor tested (Two-way ANOVA, and one-way
ANOVA followed by Tukey's t-test). The baseline mean values were: Panel A— vehicle
i.t.+saline (7.8±0.6), vehicle i.t.+G-CSF (8.7±0.2), wortmanin 0.3 μg i.t.+G-CSF
(8.6±0.5), wortmanin 1 μg i.t.+G-CSF (8.6±0.4), and wortmanin 3 μg i.t.+G-CSF
(8.5±0.2); Panel B — vehicle i.t.+saline (7.9±0.3), vehicle i.t.+G-CSF (8.4±0.2),
wortmanin 0.3 μg i.t.+G-CSF (8.7±0.4), wortmanin 1 μg i.t.+G-CSF (8.3±0.5), and
wortmanin 3 μg i.t.+G-CSF (8.6±0.4).3.8. Combined Treatment with MAP kinases and PI3K inhibitors at doses
that are ineffective as single treatment reduces G-CSF-induced hyperalgesia
Mice received single i.t. treatment with PD98059 (1 μg), SP600125
(1 μg), SB202190 (1 μg) or wortmanin (0.3 μg), or co-treatment with
1 μg of each MAP kinase inhibitors (PD98059, SP600125, SB202190)
plus 0.3 μg of wortmanin in a single injection or vehicle (5 μl of 2%
DMSO in saline) 30 min before G-CSF stimulus (Fig. 8). G-CSF induced
signiﬁcant hyperalgesia 5 h after injection, which was unaffected by
single treatment with PD98059, SP600125, SB202190 or wortmanin.
On the other hand, the combination of those inhibitors at doses that
were ineffective as single treatment signiﬁcantly inhibited G-CSF-
induced hyperalgesia (Fig. 8).
4. Discussion
Granulocyte-colony stimulating factor (G-CSF) is a current therapy
to increase neutrophil counts in peripheral blood of patients that
underwent chemotherapy or radiotherapy for cancer treatment. The
G-CSF therapy is well tolerated, but some side effects such as
abdominal pain, bone pain and muscle-skeletal pain limit its
applicability (Granulokine®, Filgrastim package insert; Battiwalla
and McCarthy, 2009). In the present study, it was demonstrated that
G-CSF-induced mechanical hyperalgesia in mice depends on spinal
activation of ERK, JNK, p38 and PI3K acting in synergy/sequence.
Furthermore, the treatment with a dose of morphine with peripheral
action also reduced G-CSF-induced hyperalgesia.
The intraplantar (subcutaneous plantar) injection of G-CSF
induced hyperalgesia in mice at a dose equivalent to the recom-
mended dose for humans of 5 μg/kg per day (Granulokine®,
Filgrastim package insert). In humans, opioid treatment is a usual
and efﬁcient approach to inhibit G-CSF therapy-induced pain. In
agreement, G-CSF-induced mechanical hyperalgesia in mice was
reduced by morphine treatment, and this effect of morphine was
inhibited by naloxone treatment. Thus, the response induced by G-CSF
inmice seems to reﬂect what is seen in humans. It is important to note
that patients may undergo G-CSF therapy for many weeks, and
chronic use of opioids raise possible issues such as side effects,
tolerance and addiction (Devulder et al., 2009). In this sense, our
study also suggests that it is worthy evaluating whether treatment
with peripherally acting opioids is a conceivable approach to control
G-CSF therapy-induced pain since morphine was effective at
peripherally acting doses (e.g. ipsilateral but not contra-lateral
treatment with morphine inhibited G-CSF hyperalgesia).
G-CSF can directly activate nociceptors since they express G-CSF
receptor (G-CSFR) (Schweizerhof et al., 2009). However, it was not
detected overt pain-like behavior by the hyperalgesic dose of 100 ng
of G-CSF. This result is consistent with the effect of other cytokines
that do not induced overt pain at hyperalgesic doses (Verri et al.,
2008b). G-CSF did not induce thermal hyperalgesia, which suggests
disagreement with previous evidence (Schweizerhof et al., 2009).
Nevertheless, the use of different thermal tests involving different
structure/mechanisms such as spinal (Hargreaves plantar test) versus
supra-spinal (hot plate test) mechanisms (Le Bars et al., 2001) might
explain these opposing results (Schweizerhof et al., 2009 and present
data, respectively). Therefore, G-CSF seems to activate spinal rather
than supra-spinal mechanisms.
A common mechanism of inﬂammatory and neuropathic pain is
the spinal activation of MAP kinases (ERK, JNK and p38) and PI3K
(Svensson et al., 2003; Ji and Strichartz, 2004; Obata et al., 2004; Xu et
al., 2007; Pezet et al., 2008; Choi et al., 2010; Fitzsimmons et al., 2010;
Gao and Ji, 2010). The activation of spinal MAP kinases and PI3K
contribute to hyperalgesia by modulating ion channels, increasing the
production of cytokines and other mediators and their receptors, and
therefore, inducing the sensitization of nociceptors (Ji & Strichartz,
2004; Gao and Ji, 2010).
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(Rausch and Marshall, 1997, 1999; Dong and Larner, 2000; Hunter
and Avalos, 2000; Kendrick et al., 2004). In agreement, inhibition of
p38, ERK, JNK, and PI3K diminished G-CSF-induced hyperalgesia in a
dose-dependent manner. Importantly, none of the intrathecal treat-
ments with kinase inhibitors altered the mechanical hyperalgesia in
the contra-lateral paw to G-CSF stimulus, indicating that PD98059,
SB600125, SB202190 and wortmanin do not alter the basal mechan-
ical threshold of normal tissue. Furthermore, the higher doses of p38,
ERK, JNK, and PI3K inhibitors abolished G-CSF-induced hyperalgesia,
which could be explained by a sequential or synergic role of spinal
p38, ERK, JNK, and PI3K in G-CSF-induced hyperalgesia. In fact, the
combined treatment with MAP kinases and PI3K inhibitors, at doses
that are ineffective as single treatment, signiﬁcantly reduced G-CSF
hyperalgesia, therefore, indicating that these pathways act in
sequence/synergy. Indicating a sequential pathway and the interac-
tion of PI3K and MAP kinases, PI3K activates ERK in primary sensory
neurons inducing heat hyperalgesia (Zhuang et al., 2004), and PI3K
activates p38 inducing cellular chemotaxis (Shahabuddin et al., 2006).
MAP kinases present a different interaction among them compared to
PI3K/MAP kinases relationship since they can act in a co-dependent
manner to activate transcription factors such as activating protein-1
(AP-1) as known for JNK and ERK (Kim and Iwao, 2003). On the other
hand, p38, ERK and JNK do not activate each other. Corroborating, ERK
and p38 inhibitors do not affect G-CSF-induced JNK activation in a
model of cell proliferation (Rausch and Marshall, 1997). Thus, the
combined treatment with MAP kinases and PI3K inhibitors could
allow reduced doses of such inhibitors (1 μg of each MAP kinase
inhibitor plus 0.3 μg of PI3K inhibitor) compared to single drug
treatment (10 μg of a single MAP kinase inhibitor or 1–3 μg of PI3K
inhibitor).
In addition to the present data, it was recently demonstrated the
endogenous role of G-CSF in a mice model of bone cancer pain
(Schweizerhof et al., 2009). The injection of pancreatic adenocarci-
noma induces an increase of G-CSF production in the paw skinFig. 8. Combined Treatment with MAP kinases and PI3K inhibitors at doses that are
ineffective as single treatment reduces G-CSF-induced hyperalgesia. Mice received
single i.t. treatment with PD98059 (1 μg), SP600125 (1 μg), SB202190 (1 μg) or
wortmanin (0.3 μg), or co-treatment with 1 μg of each MAP kinase inhibitor (PD98059,
SP600125, and SB202190) plus 0.3 μg of wortmanin or vehicle (2% DMSO in saline)
30 min before i.pl. injection with G-CSF (100 ng/paw). Mechanical hyperalgesia was
evaluated 5 h after G-CSF administration with electronic pressure meter. Results are
presented as means±s.e.m. of 5 mice per group, and are representative of 2 separated
experiments. * Pb0.05 compared to vehicle i.t.+saline group, # Pb0.05 compared to
vehicle+G-CSF control group, and inhibitors alone groups (One-way ANOVA followed
by Tukey's t-test). The baseline mean values were: vehicle i.t.+saline (8.0±0.6),
vehicle i.t.+G-CSF (8.3±0.2), PD98059 i.t.+G-CSF (7.9±0.2), SP600125 i.t.+G-CSF
(8.2±0.1), SB202190 i.t.+G-CSF (8.0±0.3), wortmanin i.t.+G-CSF (8.2±0.5), and
co-treatment (8.1±0.3).concomitantly with expression of G-CSFR by sensory dorsal root
ganglion (DRG) neurons suggesting possible direct activation of
nociceptors by G-CSF (Schweizerhof et al., 2009). Furthermore, the
treatment with anti-G-CSFR antibodies reduces tumor-induced
mechanical hyperalgesia, demonstrating the G-CSF endogenous role
in this model of cancer pain (Schweizerhof et al., 2009). G-CSF induces
ERK activation in dorsal root ganglion neurons in vitro in a PI3K and
MEK inhibitors (LY294002 and PD98059, respectively) sensitive
manner, suggesting that G-CSF-induced ERK phosphorilation depends
on prior PI3K activation (Schweizerhof et al., 2009). This result
supports our hypothesis described above in which MAP kinases and
PI3K pathways are interconnected and sequentially/synergistically
mediate G-CSF hyperalgesia. Corroborating a role for G-CSF-triggered
mechanisms in tumor-induced hyperalgesia, PD98059 treatment also
inhibits carcinoma-induced hyperalgesia (Schweizerhof et al., 2009).
Thus, Schweizerhof et al. (2009) demonstrated that endogenous
G-CSF mediates tumor-induced hyperalgesia in a PI3K/ERK-dependent
pathway. Nevertheless, it was not addressed whether the hyper-
algesia induced byG-CSF administration could be diminished byMAP
kinases or PI3K inhibitors, which is an experimental condition that
could shed light in the pain mechanisms triggered by G-CSF therapy
as demonstrated herein.
The present study conﬁrmed that G-CSF induces mechanical
hyperalgesia, and advanced by demonstrating an in vivo role of spinal
MAP kinases (ERK, JNK and p38) and PI3K in G-CSF-induced
mechanical hyperalgesia in mice.Acknowledgments
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